Molecular Partners AG ADR Dossier
Qualitative Analysis
Business overview
Molecular Partners AG is a clinical-stage biopharmaceutical company pioneering the design and development of DARPin (Designed Ankyrin Repeat Protein) therapeutics. DARPins represent a novel class of custom-built protein drugs engineered to address medical challenges that traditional drug modalities, such as monoclonal antibodies, cannot easily target. The company's proprietary platform leverages the unique properties of DARPins—including high specificity, picomolar affinity, small size, and flexible multi-specific architecture—to develop highly differentiated therapies. Molecular Partners focuses primarily on oncology, targeted radiopharmaceuticals (Radio-DARPin Therapeutics, or RDTs), and immunology. Its lead clinical-stage assets include MP0712, a DLL3-targeting targeted alpha therapy co-developed with Orano Med, and MP0317, a tumor-localized CD40 agonist.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing a pipeline of targeted radiotherapeutics (Radio-DARPins) designed as isotope-agnostic vectors capable of delivering various alpha-emitting radioactive payloads (such as Lead-212 and Actinium-225) directly to tumor cells.
Expected impact: Enables precise delivery of potent radioactive payloads to tumor lesions while minimizing damage to healthy tissues, positioning the company as a leader in alpha-targeted radiotherapy.
Implementation of a strategic restructuring plan, including a workforce reduction of up to 40 positions (~24% of total staff), to prioritize high-potential clinical assets and optimize capital allocation.
Expected impact: Significantly lowered operating expenditures and extended the company's cash runway to support key clinical milestones without immediate dilutive financing.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Expands the therapeutic potential of the Radio-DARPin platform by enabling the use of Actinium-225 (225Ac) as a therapeutic alpha-emitting isotope payload, supporting the company's isotope-agnostic strategy.
Terms: Non-exclusive development agreement; detailed financial terms were not disclosed.
Secures access to Lead-212 (212Pb) isotope supply and clinical manufacturing slots for up to ten radiotherapy programs, including the lead candidate MP0712.
Terms: Expanded agreement to co-develop up to ten radiotherapy programs; specific financial terms were not disclosed.